ARQT

Arcutis Biotherapeutics, Inc. (ARQT) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on dermatological diseases. Its primary commercial product is ZORYVE (roflumilast), available in various formulations (cream and foam) and concentrations for plaque psoriasis, seborrheic dermatitis, and atopic dermatitis. The company also has a pipeline asset, ARQ-234, currently in Phase 1a/1b clinical trials for atopic dermatitis.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Product revenue increased 59% in Q2 2026 compared to Q2 2025, driven by higher demand for ZORYVE cream 0.3%, ZORYVE foam (seborrheic dermatitis and scalp psoriasis), and ZORYVE cream 0.15% (atopic dermatitis). The launch of ZORYVE cream 0.05% in late 2025 also contributed.
• Profitability: The company reported a net income of $15.0 million in Q2 2026, a significant turnaround from a net loss of $15.9 million in the same period in 2025. Operating income turned positive ($16.4 million) from a loss of $14.6 million.
• Expense Increases:
  • R&D Expenses: Increased 38% year-over-year for the six months ended June 30, primarily due to a $10.0 million milestone payment to former Ducentis stockholders triggered by the first patient dosing in the ARQ-234 Phase 1 trial.
  • SG&A Expenses: Increased 19% in Q2 2026, driven by higher compensation costs (expansion of the dermatology sales force) and marketing spend, partially offset by the termination of the Kowa promotion agreement in January 2026.
• Debt Structure: The company paid a $1.0 million prepayment penalty in Q2 2026 related to a 2024 partial prepayment. A final fee of $6.95 million is due on January 4, 2027. The interest rate on the loan is floating (5.95% + SOFR/floor), standing at 9.57% as of June 30, 2026.

Guidance, Outlook, and Risks

• Liquidity: Management believes existing capital resources ($238.9 million in cash/securities) are sufficient to meet operating requirements for at least 12 months. No immediate financing is anticipated, though future needs depend on commercialization success and clinical trial costs.
• Commercial Strategy: Following the termination of the Kowa promotion agreement, Arcutis has assumed full responsibility for promoting ZORYVE to primary care and pediatrics, utilizing its own dedicated commercial team.
• Clinical Pipeline:
  • ARQ-234: Phase 1a/1b trial initiated in March 2026 for atopic dermatitis.
  • ZORYVE Label Expansions: An sNDA for ZORYVE cream 0.05% for infants (3 months to 2 years) was submitted to the FDA with a PDUFA date of February 23, 2027.
• Risks:
  • Patent Litigation: Ongoing litigation against Padagis regarding a generic version of ZORYVE cream 0.3%. The case is currently stayed, but the 30-month stay of FDA approval for the generic is set to expire on August 14, 2026, unless extended by the stay.
  • Debt Covenants: The company must maintain minimum net product revenue equal to 75% of its projected annual plan on a trailing six-month basis.

Investor Verification Checklist

• Debt Obligations: Verify the timing and impact of the $6.95 million final fee due in January 2027 and the floating interest rate exposure (currently 9.57%).
• Patent Stay Expiration: Monitor the status of the Padagis litigation stay, which is set to expire August 14, 2026, potentially impacting generic competition for ZORYVE cream 0.3%.
• Commercial Execution: Assess the performance of the internal sales team following the termination of the Kowa partnership in January 2026.
• ARQ-234 Milestones: Track the progress of the Phase 1a/1b trial and potential future contingent payments (up to $386 million remaining) to Ducentis stockholders.
• Regulatory Approvals: Watch for the FDA decision on the ZORYVE cream 0.05% sNDA for infants (PDUFA date: Feb 23, 2027).